In January – August 2017, the imports of active pharmaceutical ingredients (APIs) to Russia amounted to 48.9 billion rubles (in prices set for release to free circulation, including VAT).
Most of this amount (97.4%) relates to supplies of pharmacopoeial APIs. Compared to the same period of the previous year, the total supplies increased by 28% in ruble terms, with pharmacopoeial APIs making the greatest contribution to these dynamics. In one year, the deliveries of APIs jumped by 29%, while the imports of technical raw materials declined by 2.4%.
It is interesting to note that the dynamics of supplies in physical terms, firstly, is not impressive (only a 9.9% increase comparing to previous year) and, secondly, the pace of imports of pharmacopoeial raw materials is lower than the dynamics reported for supplies of technical APIs (9.7% and 15.7%, respectively). Overall, since the beginning of this year, the imports of APIs to Russia amounted to about 8.02 thousand tons.
The bulk of imports (in monetary terms) to the Russian Federation and the most diverse range of APIs come from China. In the period since the beginning of 2017, this segment accounted for 19.7% of imports, with a total number of 336 imported APIs.
Ireland was the absolute record holder in terms of supply dynamics – this year the imports of APIs from that country was almost 600 times larger in monetary terms. Only 3 products are imported from Ireland and, in this case, almost 95% of supplies in monetary terms involve antigens for manufacturing the preventive vaccine against pneumococcal infections.
A lowest result among the top suppliers had Ukraine. This year, the imports of APIs from that country to Russia fell by 57% in ruble terms, even despite the fact that the range of supplied products expanded from 13 to 15 over the same period.